DeLLphi-305 Interim Analysis: Durvalumab Plus Tarlatamab First-Line Maintenance Cuts Death Risk 58% in Extensive-Stage Small Cell Lung Cancer

In the Phase III DeLLphi-305 trial, first-line maintenance durvalumab plus tarlatamab reduced the risk of death by 58% versus durvalumab alone in extensive-stage small cell lung cancer. Median OS was 21.1 months with the combination versus 12.7 months with monotherapy (OS HR 0.42; 95% CI 0.32-0.54; p<0.001). Median PFS was 7.4 versus 1.9 months (PFS HR 0.34; 95% CI 0.28-0.42; p<0.001).